News - Biotechnology, Licensing, Financial


1 to 25 of 50 results

Epizyme earns $4 million milestone under GSK collaboration


US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…


Robust 2013 for biotech licensing deals; average up-front payment jump 60%


Biotech licensing deals have been trending up markedly in recent months, according to the new installment…


Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave


French biotech firm TxCell SA and privately-held Switzerland-headquartered Ferring International have…

BiotechnologyFerring PharmaceuticalsFinancialGastro-intestinalsLicensingOvaSaveTxCell

Another milestone for GenVec in hearing and balance collaboration


US biotech firm GenVec says it has achieved the third milestone in its collaboration with Swiss drug…


Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone


Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…


arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer


Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Mersana Therapeutics reaches second preclinical milestone in Endo collaboration


Privately-held US biotech company Mersana Therapeutics has achieved its second preclinical milestone…

BiotechnologyEndo PharmaceuticalsFinancialLicensingMersanaOncologyResearchUSA

Strong third quarter for early-stage biotech licensing deals


Life sciences companies enjoyed a healthy surge in licensing deals during third quarter 2013, according…


Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring


US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Vertex sells Incivo royalty rights to Janssen for $152 million


Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline


US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

MorphoSys closes on the alliance with Celgene


German biotech firm MorphoSys (FSE: MOR) that its MOR202 alliance with Celgene (Nasdaq: CELG), the world's…


Tengion closes deals to advance organ regeneration platform


USA-based Tengion (OTCQB: TNGN), a leader in regenerative medicine, says it has now closed transactions…


Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill


A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

Medigene secures SynCore as global partner for EndoTAG-1


German biotech firm Medigene (MDG: GR) has secured SynCore Biotechnology (part of Taiwan's Sinphar Pharmaceutical…

BiotechnologyEndoTAG-1FinancialLicensingMedigeneSynCore Biotechnology

Neovacs moving forward in rheumatoid arthritis, say analysts


French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead…


Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs


US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Regeneron acquires rights to two ophthalmology programs from Sanofi


US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…


Two life sciences IPOs and strengthening markets offer encouragement to Biotech sector


Two companies focused on infectious disease successfully completed initial public offerings (IPOs) in…

BiotechnologyFinancialLicensingMergers & Acquisitions

RXi Pharma and OPKO Health pooling RNAi assets


US biotech firm RXi Pharmaceuticals (Nasdaq: RXII) and OPKO Health (NYSE: OPK) have entered into a strategic…

BiotechnologyFinancialLicensingOPKO HealthPharmaceuticalRXi Pharmaceuticals

Spain's Zeltia is turning a corner, say Edison analysts


Spanish drugmaker Grupo Zeltia (ZEL: MC) is approaching a material catalyst this year in the form of…


Infinity amends PI3K-delta, gamma accord with Millennium


US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK


NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

News briefs: Celgene deal with Sutro; Amgen pleads guilty to misbranding


US biotech firm Celgene Corp (Nasdaq: CELG) has entered a collaboration with San Francisco-based Sutra…

AmgenAranespBiotechnologyCelgeneFinancialLegalLicensingNorth AmericaSutro Biopharma

1 to 25 of 50 results

Back to top